# Michael Davis

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/michael-davis
Canonical HTML page: https://getbiobrief.com/entity/michael-davis

## Timeline

- **2026-09-08**: HHS announces permanent FDA center directors — Four senior positions filled, including permanent directors for drugs, vaccines/biologics, and tobacco products.
- **2026-09-08**: HHS fills four senior FDA roles — The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
- **2026-05**: Tracy Beth Høeg departs CDER — Høeg says she was fired as director of the FDA's Center for Drug Evaluation and Research.
- **2026-05**: Michael Davis assumes acting CDER director — Davis steps in as acting director of CDER following Høeg's departure.
- **2026-05**: Hoeg departs CDER — Dr. Tracy Beth Hoeg said she was fired from the Center for Drug Evaluation and Research; Davis began serving in an acting role.
- **2025**: Michael Davis returns to FDA as deputy director — Davis rejoins the agency after working at a nonprofit pursuing psychedelic drug development.
- **2025**: Davis returns to FDA — Michael Davis rejoined the agency as a deputy director after working at a nonprofit pursuing psychedelic drug development.

## Recent coverage (2 stories)

### FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
2026-09-09 21:53:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Full story: https://getbiobrief.com/story/fda-psychedelic-drug-chief-vaccine-director-biotech-impact-2026

### FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
2026-09-09 16:42:11 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The FDA's new permanent CDER director is Michael Davis, whose psychiatric drug and psychedelic nonprofit background aligns with White House calls for faster psilocybin, MDMA, and LSD reviews. Vaccine and tobacco center leadership also stabilized.
Full story: https://getbiobrief.com/story/fda-cder-psychedelics-biotech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.